All these findings have prompted to consider monoclonal antibodies against VEGF and VEGFR tyrosine kinase inhibitors (TKIs) as a possible treatment for lung NETs (9, 10, 15–21). This evidence concerns the gene VEGFA and lung neuroendocrine neoplasm.